Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors.
Bhide, R.S., Keon, A., Weigelt, C., Sack, J.S., Schmidt, R.J., Lin, S., Xiao, H.Y., Spergel, S.H., Kempson, J., Pitts, W.J., Carman, J., Poss, M.A.(2017) Bioorg Med Chem Lett 27: 4908-4913
- PubMed: 28947151 
- DOI: https://doi.org/10.1016/j.bmcl.2017.09.029
- Primary Citation of Related Structures:  
5W84, 5W85, 5W86 - PubMed Abstract: 
The identification of small molecule inhibitors of IRAK4 for the treatment of autoimmune diseases has been an area of intense research. We discovered novel 4,6-diaminonicotinamides which potently inhibit IRAK4. Optimization efforts were aided by X-ray crystal structures of inhibitors bound to IRAK4. Structure activity relationship (SAR) studies led to the identification of compound 29 which exhibited sub-micromolar potency in a LTA stimulated cellular assay.
Organizational Affiliation: 
Discovery Chemistry, Research & Development, Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, NJ 08543, United States. Electronic address: bhider09@gmail.com.